BCL2 and hematopoietic and lymphoid system neoplasm: Venetoclax is a BCL2-specific inhibitor whose use is expanding in hematologic malignancies.20,21 However, blood cancer cells frequently engage distinct mechanisms that can maintain survival following BCL2 inhibition.